[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mucopolysaccharidosis-vi\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mucopolysaccharidosis-vi":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,56],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":17,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":33,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100486886","registry-of-patients-diagnosed-with-lysosomal-storage-diseases-100486886",false,"NCT05619900","Registry of Patients Diagnosed With Lysosomal Storage Diseases","LSD Registry","Inclusion Criteria:\n\n* Patients aged 0-64 with a diagnosis of a lysosomal storage disease\n* Pregnant patients whose fetus has a diagnosis of a lysosomal storage disease\n\nExclusion Criteria:\n\n* There are no current exclusion criteria","ALL","64 Years",{"count":19,"type":20},250,"ESTIMATED","15 Years","OBSERVATIONAL","This is an international prospective and retrospective registry of patients with Lysosomal Storage Diseases (LSDs) to understand the natural history of the disease and the outcomes of fetal therapies, with the overall goal of improving the prenatal management of patients with LSDs.",[25,26,27,28,29,30,31,32],"Mucopolysaccharidosis I","Mucopolysaccharidosis II","Mucopolysaccharidosis IV A","Mucopolysaccharidosis VI","Mucopolysaccharidosis VII","Pompe Disease Infantile-Onset","Neuronopathic Gaucher Disease","Wolman Disease",[34,35,36,37,38,39,25,26,40,28,29,30,31,32,41,42],"Lysosomal Storage Disease","LSDs","Inborn Error of Metabolism","Hurler Syndrome","Sly Syndrome","Hunter Syndrome","Mucopolysaccharidosis IVa","MPS","Mucopolysaccharidosis","RECRUITING","2026-04-06",{"date":46,"type":47},"2026-04-08","ACTUAL",{"date":49,"type":47},"2022-05-31",{"date":51,"type":20},"2050-05-31",{"name":53,"class":54},"University of California, San Francisco","OTHER",1,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":4,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":63,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":65,"conditions":66,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":81},"100518911","mps-radico-cohort-radico-mps-100518911","NCT06036693","MPS (RaDiCo Cohort) (RaDiCo-MPS)","Mucopolysaccharidosis Patients in France in the Era of Specific Therapeutics","Inclusion Criteria:\n\n* Confirmed diagnosis of MPS based on clinically relevant enzyme deficiency, with abnormally elevated GAG urinary excretion and\u002For identification of pathogenic mutations.\n* Signed informed consent or parents\u002Fguardian non-opposition for deceased patients (minor or protected major)\n\nThere are no non-inclusion criteria.",{"count":64,"type":20},1000,"The goal of this observational study is to characterize the epidemiology and natural history of MPS diseases by building a retrospective and prospective collection of extensive phenotypic data from French MPS patients.",[25,26,67,68,28,29,69,70],"Mucopolysaccharidosis III","Mucopolysaccharidosis IV","Mucopolysaccharidosis IX","Multiple Sulfatase Deficiency Disease","2026-02-10",{"date":73,"type":47},"2026-02-11",{"date":75,"type":47},"2017-12-20",{"date":77,"type":20},"2026-12",{"name":79,"class":80},"Institut National de la Santé Et de la Recherche Médicale, France","OTHER_GOV",23]